The Oncology Institute, Inc. TOI Oral drug accounts receivable — Total Assets
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s oral drug accounts receivable — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s oral drug accounts receivable — total assets?
- The Oncology Institute, Inc. (TOI) reported oral drug accounts receivable — total assets of $10M in Q1 2026.
- How has The Oncology Institute, Inc.'s oral drug accounts receivable — total assets changed year-over-year?
- The Oncology Institute, Inc.'s oral drug accounts receivable — total assets increased by 31.1% year-over-year, from $7.62M to $10M.
- What does oral drug accounts receivable — total assets mean?
- This metric measures the proportion of total assets tied up in outstanding receivables specifically generated by the oral drug dispensary segment. It serves as an indicator of the efficiency of the company's revenue cycle management and the liquidity risk associated with its pharmaceutical distribution operations. A higher ratio may suggest challenges in collecting payments from payers or patients for oral oncology medications, potentially impacting overall capital efficiency.